Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses

Breast Reconstruction Clinical Trial

Official title:

Core Gel Study of the Safety and Effectiveness of Mentor Round Low Bleed Silicone Gel-filled Mammary Prostheses in Patients Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00753922
• Other study ID #: 10-009-0799-01
• Status: Completed
• Phase: Phase 3
• First received: September 15, 2008
• Last updated: March 21, 2014
• Start date: September 2000
• Est. completion date: June 2012

Study information

• Verified date: March 2014
• Source: Mentor Worldwide, LLC
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The Core Gel Study is designed to demonstrate safety and effectiveness of Mentor's Round Low-Bleed Silicone Gel-filled Mammary Prostheses in women who are undergoing primary augmentation, primary reconstruction, or revision. Safety information on the rate of capsular contracture, rupture, and infection will be collected, and used to help determine device safety.

Approximately 1000 patients at centers across the United States will be enrolled in this research study. These patients will be implanted with silicone breast prostheses and monitored for 10 years to collect information on risks associated with the implant surgery as well as changes in the way these patients feel about themselves.

Description:

Silicone gel-filled breast implants were introduced in the early sixties and were in wide-scale distribution by the time the Medical Device Amendments to the Food Drug and Cosmetic Act was passed in 1976. In 1983, gel-filled breast implants were designated as Class III devices requiring premarket approval. In May 1990, the Food and Drug Administration (FDA) published a proposed request (515(b)) for Premarket Approval Applications (PMA) and in April 1991 published the final request. This final publication put manufacturers of gel-filled breast implants on notice that for continued marketing of gel-filled breast implants, a PMA was due to FDA in 90 days from the final publication date.

A premarket approval (PMA) for the Mentor gel-filled breast implants was filed with the FDA in July 1991. At the FDA General and Plastic Surgery Advisory Committee meeting in November 1991, the committee recommended the submission of additional information to establish the safety and effectiveness of gel-filled breast implants.

In January 1992, the FDA Commissioner announced a voluntary moratorium of the sale of gel-filled breast implants to allow the advisory panel time to assess additional information. In April 1992, the moratorium was lifted but only for reconstruction and revision patients. Every patient implanted had to be part of an adjunct study, and had to be offered participation in a registry of gel-filled breast implant patients. In order to be implanted with gel-filled implants for augmentation, women had to be enrolled in a core clinical study.

The objective of this study is to determine the safety and effectiveness of the smooth and textured surface Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses in women who are undergoing primary breast augmentation, primary breast reconstruction or revision.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1008
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is Genetic female and at least 18 years old

• A candidate for:

• Primary breast augmentation (for post-lactational mammary involution or general breast enlargement)

• Primary breast reconstruction (for cancer, trauma, surgical loss of breast or congenital deformity)

• Revision surgery (previous augmentation or reconstruction with silicone-filled or saline-filled implants)

• Signs the Informed Consent

• Agrees to follow the procedures for explant analysis

• Agrees to comply with follow-up procedures, including returning for all follow-up visits

Exclusion Criteria:

• Patient is pregnant

• Has nursed a child within three months of study enrollment

• Been implanted with any silicone implant other than breast implants (e.g. silicone artificial joints or facial implants)

• Confirmed diagnosis of the following rheumatic diseases or syndromes: SLE, Sjogren's syndrome, scleroderma, polymyositis, or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infections arthritis, spondylarthropathies, any other inflammatory arthritis, osteoarthritis, fibromyalgia, or chronic fatigue syndrome

• Currently has a condition that could compromise or complicate wound healing (except reconstruction patients)

• Patient in Augmentation cohort and has diagnosis of active cancer of any type

• Infection or abscess anywhere in the body

• Demonstrates tissue characteristics which are clinically incompatible with implant (e.g. tissue damage resulting from radiation, inadequate tissue, or compromised vascularity)

• Possesses any condition, or is under treatment for any condition which, in the opinion of the investigator and/or consulting physicians(s), may constitute an unwarranted surgical risk

• Anatomic or physiologic abnormality which could lead to significant postoperative adverse events

• Demonstrates characteristics that are unrealistic/unreasonable with the risks involved with the surgical procedure

• Premalignant breast disease without a subcutaneous mastectomy

• Untreated or inappropriately treated breast malignancy, without mastectomy

• Implanted metal or metal devices, history of claustrophobia or other condition that would make a MRI scan prohibitive

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Augmentation
• Breast Reconstruction
• Breast Revision

Intervention

Device:
• Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface
Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.

Locations

Country	Name	City	State
United States	Mentor Worldwide, LLC	Santa Barbara	California

Sponsors (1)

Lead Sponsor	Collaborator
Mentor Worldwide, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Any Reoperation	Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.	10 years	Yes
Primary	Overall Mean Change in Circumferential Chest Size	Change in Chest Size was calculated by subtracting the chest circumference prior to surgery from the chest circumference measured at the end of the study	Change from baseline to 10 years post-baseline	No
Primary	10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Baker III, IV Capsular Contracture	Baker III was identified as "firm with visible distortion" and Baker IV was identified as "obvious spherical distortion". Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.	10 Years	Yes
Primary	10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Infection	Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.	10 Years	Yes
Primary	10-Year Kaplan-Meier Estimated Cumulative Incidence Rate of Occurrence of Explantation With or Without Replacement	Time of occurrence calculated as the number of days from the date of the implant procedure to the onset date of the event. Patients were censored as of the date of their last office visit, the 120 month time point, or the date of explantation of all initial study devices, whichever was earliest.	10 Years	Yes

External Links

•   Link